Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type

被引:42
作者
Lin, Douglas I. [1 ]
Chudnovsky, Yakov [2 ]
Duggan, Bridget [3 ]
Zajchowski, Deborah [4 ]
Greenbowe, Joel [2 ]
Ross, Jeffrey S. [2 ,5 ]
Gay, Laurie M. [2 ]
Ali, Siraj M. [2 ]
Elvin, Julia A. [2 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA
[2] Fdn Med Inc, Cambridge, MA USA
[3] South Coast Gynecol Oncol Inc, San Diego, CA USA
[4] Clear Fdn, San Diego, CA USA
[5] Albany Med Coll, Dept Pathol & Lab Med, Albany, NY 12208 USA
关键词
Ovarian small cell carcinoma; Hypercalcemia; SMARCA4; SWI/SNF; BRG1; PD-1; BLOCKADE; CANCER; EXPRESSION; BRG1; MANAGEMENT; DIAGNOSIS;
D O I
10.1016/j.ygyno.2017.09.031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Small cell carcinoma of the ovary, hypercalcemic-type (SCCOHT) is a rare, extremely aggressive neoplasm that usually occurs in young women and is characterized by deleterious germline or somatic SMARCA4 mutations. We performed comprehensive genomic profiling (CGP) to potentially identify additional clinically and pathophysiologically relevant genomic alterations in SCCOHT. Methods. CGP assessment of all classes of coding alterations in up to 406 genes commonly altered in cancer and intronic regions for up to 31 genes commonly rearranged in cancer was performed on 18 SCCOHT cases (16 exhibiting classic morphology and 2 cases exhibiting exclusive a large cell variant morphology). In addition, a retrospective database search for clinically advanced ovarian tumors with genomic profiles similar to SCCOHT yielded 3 additional cases originally diagnosed as non-SCCOHT. Results. CGP revealed inactivating SMARCA4 alterations and low tumor mutational burden (TMB) (<6 mutations/Mb) in 94% (15/16) of SCCOHT with classic morphology. In contrast, both (2/2) cases exhibiting only large cell variant morphology were hypermutated (TMB scores of 90 and 360 mut/Mb) and were wildtype for SMARCA4. In our retrospective search, an index ovarian cancer patient harboring inactivating SMARCA4 alterations, initially diagnosed as endometrioid carcinoma, was re-classified as SCCOHT and responded to an SCCOHT chemotherapy regimen. Conclusion. The vast majority of SCCOHT demonstrate genomic SMARCA4 loss with only rare co-occurring alterations. Our data support a role for CGP in the diagnosis and management of SCCOHT and of other lesions with overlapping histological and clinical features, since identifying the former by genomic profile suggests benefit from an appropriate regimen and treatment decisions, as illustrated by an index patient. (c) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:626 / 633
页数:8
相关论文
共 34 条
[1]   Prophylactic oophorectomy for hereditary small cell carcinoma of the ovary, hypercalcemic type [J].
Berchuck, Andrew ;
Witkowski, Leora ;
Hasselblatt, Martin ;
Foulkes, William D. .
GYNECOLOGIC ONCOLOGY REPORTS, 2015, 12 :20-22
[2]   A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes [J].
Bultman, S ;
Gebuhr, T ;
Yee, D ;
La Mantia, C ;
Nicholson, J ;
Gilliam, A ;
Randazzo, F ;
Metzger, D ;
Chambon, P ;
Crabtree, G ;
Magnuson, T .
MOLECULAR CELL, 2000, 6 (06) :1287-1295
[3]   Characterization of mammary tumors from Brg1 heterozygous mice [J].
Bultman, S. J. ;
Herschkowitz, J. I. ;
Godfrey, V. ;
Gebuhr, T. C. ;
Yaniv, M. ;
Perou, C. M. ;
Magnuson, T. .
ONCOGENE, 2008, 27 (04) :460-468
[4]   Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases* [J].
Callegaro-Filho, D. ;
Gershenson, D. M. ;
Nick, A. M. ;
Munsell, M. F. ;
Ramirez, P. T. ;
Eifel, P. J. ;
Euscher, E. D. ;
Marques, R. M. ;
Nicolau, S. M. ;
Schmeler, K. M. .
GYNECOLOGIC ONCOLOGY, 2016, 140 (01) :53-57
[5]   Absolute quantification of somatic DNA alterations in human cancer [J].
Carter, Scott L. ;
Cibulskis, Kristian ;
Helman, Elena ;
McKenna, Aaron ;
Shen, Hui ;
Zack, Travis ;
Laird, Peter W. ;
Onofrio, Robert C. ;
Winckler, Wendy ;
Weir, Barbara A. ;
Beroukhim, Rameen ;
Pellman, David ;
Levine, Douglas A. ;
Lander, Eric S. ;
Meyerson, Matthew ;
Getz, Gad .
NATURE BIOTECHNOLOGY, 2012, 30 (05) :413-+
[6]   Selective Killing of SMARCA2-and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models [J].
Chan-Penebre, Elayne ;
Armstrong, Kelli ;
Drew, Allison ;
Grassian, Alexandra R. ;
Feldman, Igor ;
Knutson, Sarah K. ;
Kuplast-Barr, Kristy ;
Roche, Maria ;
Campbell, John ;
Ho, Peter ;
Copeland, Robert A. ;
Chesworth, Richard ;
Smith, Jesse J. ;
Keilhack, Heike ;
Ribich, Scott A. .
MOLECULAR CANCER THERAPEUTICS, 2017, 16 (05) :850-860
[7]   Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions [J].
Clement, PB .
MODERN PATHOLOGY, 2005, 18 :S113-S129
[8]   Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type [J].
Conlon, Niamh ;
Silva, Annacarolina ;
Guerra, Esther ;
Jelinic, Petar ;
Schlappe, Brooke A. ;
Olvera, Narciso ;
Mueller, Jennifer J. ;
Tornos, Carmen ;
Jungbluth, Achim A. ;
Young, Robert H. ;
Oliva, Esther ;
Levine, Douglas ;
Soslow, Robert A. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (03) :395-403
[9]  
DICKERSIN GR, 1982, CANCER-AM CANCER SOC, V49, P188
[10]   Microsatellite Instability as a Biomarker for PD-1 Blockade [J].
Dudley, Jonathan C. ;
Lin, Ming-Tseh ;
Le, Dung T. ;
Eshleman, James R. .
CLINICAL CANCER RESEARCH, 2016, 22 (04) :813-820